Evaluating mAbs binding abilities to Omicron subvariant RBDs: implications for selecting effective mAb therapies
Description
The ongoing evolution of the Omicron lineage of SARS-CoV-2 has led to the emergence of subvariants that pose challenges to antibody neutralization. Understanding the binding dynamics between the receptor-binding domains (RBD) of these subvariants
